Skip to content

ICU Norepinephrine Load

Norepinephrine Load and Relationship With Prognosis in Critically Patients With Circulatory Shock

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05032261
Acronym
ICU_NE_LOAD
Enrollment
100
Registered
2021-09-02
Start date
2021-09-01
Completion date
2024-12-31
Last updated
2025-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Circulatory Collapse and Shock

Keywords

Norepinephrine load dose, vasopressor dose intensity, vasopressor exposure

Brief summary

Norepinephrine is recommended as first-line vasopressor in critically ill patients, regardless of shock etiology. Its advantages over dopamine and/or epinephrine have been demonstrated, especially by reducing tachycardia events. The current guidelines recommend a mean arterial pressure of at least 65 mmHg that in the resuscitation from sepsis-induced hypoperfusion. Some study reported that delay in initiation of vasopressor therapy was associated with an increase mortality risk in patient with septic shock .The recent experts' opinion suggest that vasopressors should be started early, before (complete) completion of fluid ressuscitation . In the event of refractory septic shock, high-dose vasopressors may be used. The precise maximal dose of norepinephrine associated with mortality excess has been poorly studied. High doses have been defined by a cutoff value ranging from 0.5 μg/kg/min to 2 μg/kg/min and recently by 1 μg/kg/min for mortality at 90% and by 0,75 μg/kg/min for mortality at 60%. Furthermore, an increasing vasopressor dosing intensity during the first 24 hours after shock septic was associated with increased mortality depending of fluid administration. If a threshold value of norepinephrine score can be obtained, it could indicate the association with another vasopressor such as vasopressin or surrogates. The primary aim of the present study aimed to confirm if a given norepinephrine dose is associated with mortality. The secondary aims were the link between mortality and norepinephrine duration, cumulative dose in order to build a score that predicts a futility of increasing norepinephrine dose.

Interventions

DRUGCirculatory shock with norepinephrine in ICU

Circulatory shock with norepinephrine in ICU

Sponsors

Centre Hospitalier Universitaire de Nīmes
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age \> 18 years * circulatory shock and admitted in ICU * with norepinephrine

Exclusion criteria

: Patient without norepinephrine or missing data.

Design outcomes

Primary

MeasureTime frameDescription
MortalityDay 5Mortality within 5 days of the date of ICU admission for circulatory shock according to norepinephrine intensity

Secondary

MeasureTime frameDescription
IntensityDay 5Intensity mortality relationship according to norepinephrine duration
Time/Dose RatioDay 5ratio between time of use and cumulative dose
Norepinephrine doseDay 5score of increasing norepinephrine dose

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026